Scleromyxedema is a clinical variant of the rare disease papular mucinosis that has both cutaneous and systemic manifestations. Treatment options are numerous and tend to be associated with serious potential side effects and frequent relapse.
Objective:
We report a case of scleromyxedema treated with low-dose oral prednisone and intravenous immunoglobulin (IVIg). This is followed by a review of the literature.
Conclusion:
IVIg is being used for a growing number of inflammatory and immune disorders. It is being increasingly reported as a successful treatment for scleromyxedema. Although our patient succumbed to the disease, combination therapy with prednisone and IVIg provided temporary symptomatic, laboratory, and clinical improvement of the condition. Optimization of this therapeutic strategy is thus indicated for the management of scleromyxedema.
DubreuilhW. Fibromes miliaires folliculaires: Sclerodermie consecutive. Ann Dermatol Syph1906; 37:569–572.
3.
ReitmannK. Uber eine eigenartige, der sklerodermie nahestehende affektion. Arch Dermatol Syph1908; 92:417–424.
4.
CaradonnaSJacobeH. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol2004; 140:277–280.
5.
PomannJJRudnerEJ. Scleromyxedema revisited. Int J Dermatol2003;42:31–35.
6.
DinneenAMDickenCH. Scleromyxedema. J Am Acad Dermatol1995; 33:37–43.
7.
ListerRKJollesSWhittakerS. Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol2000; 43:403–408.
8.
KarimABlackMMLawlorF. Case 5: Extensive skin eruption causing skin to become tight, sore, and itchy. Diagnosis: Scleromyxoedema. Clin Exp Dermatol2003; 28:343–344.
9.
PenmetchaMHighetASHopkinsonJM. Failure of PUVA in lichen myxedematosus: Acceleration of associated multiple keratoacanthomas with development of squamous cell carcinoma. Clin Exp Dermatol1987; 12:220–223.
YaronMYaronIYustI. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol1985; 12:171–175.
LaiAFatRFMSuurmondD. Scleromyxedema (lichen myxedematous) associated with a paraprotein IgG of type Kappa. Br J Dermatol1973; 88:107–116.
14.
JablonskaS, ed. Scleroderma and Pseudosclerderma2nd ed.Polish Medical Publishers, Warsaw1975, pp 407–411.
15.
FleischmajerR. Papular mucinosis. In: FreedbergIMEisenAZWolffK, Fitzpatrick's Dermatology in General Medicine6th ed.New York: McGraw–Hill, 2003; pp 1803–1805.
16.
KulczyckiANelsonMEisenA. Scleromyxoedema: Treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol2003; 149:1276–1281.
17.
BrennerSYustI. Treatment of scleromyxedema with etretinate. J Am Acad Dermatol1984; 10:295–296.
18.
MilamCPCohenLEFenskeNA. Scleromyxedema: Therapeutic response to isotretinoin in three patients. J Am Acad Dermatol1988; 19:469–477.
19.
HislerBMSavoyLBHashimotoK. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol1988; 19:854–857.
20.
HornKBHornMASwanJ. A complete and durable clinical response to high-dose dexamethasone in a patient with Scleromyxedema. J Am Acad Dermatol2004; 51:S120–S123.
21.
TschenJAChangJR. Scleromyxedema: Treatment with interferon alfa. J Am Acad Dermatol1999; 40:303–307.
22.
DavisLSSanalSSanguezaOP. Treatment of Scleromyxedema with 2-chlorodeoxyadenosine. J Am Acad Dermatol1996; 35:288–290.
23.
CohenAMHodarEDavidM. Beneficial effect of granulocyte-colony stimulating factor in Scleromyxedema associated with severe idiopathic neutropenia. Br J Dermatol1996; 135:626–629.
24.
MacFarlaneAWDavenportAVerbovJL. Scleromyxoedema: Successful treatment with plasma exchange and immunosuppression. Br J Dermatol1987; 117:653–657.
25.
WestheimAILookingbillDP. Plasmapheresis in a patient with Scleromyxedema. Arch Dermatol1987; 123:786–789.
26.
KaufmanDTruhaAPRoenigkHHJr. Scleromyxedema: Systemic manifestations and cosmetic improvement with dermabrasion. Cutis1987; 39:321–324.
27.
LoweNJDuftonPAHunterRD. Electron-beam treatment of scleromyxoedema. Br J Dermatol1982; 106:449–453.
28.
BerksonMLazarusGSUberti-BenzM. Extracorporeal photochemotherapy: A potentially useful treatment for Scleromyxedema. J Am Acad Dermatol1991; 25:724.
29.
FarrPMIveFA. PUVA- treatment of scleromyxoedema. Br J Dermatol1984; 110:347–350.
30.
FeldmanPShapiroLPickAI. Scleromyxedema: A dramatic response to melphalan. Arch Dermatol1969; 99:51–56.
31.
HarrisRBPerryHOKyleRA. Treatment of scleromyxedema with melphalan. Arch Dermatol1979; 115:295–299.
32.
SchubertKSteinAMeurerM. Initial scleromyxedema. Successful treatment with melphalan. Hautarzt2002; 53:478–482.
33.
JessenRTStraightMBeckerLE. Lichen myxedematosus: Treatment with cyclophosphamide. Int J Dermatol1978; 17:833–839.
34.
KrajncI. Arndt–Gottron scleromyxedema: Summary of 2 years treatment. Wien Klin Wochenschr1997; 109:960–963.
35.
Bata-CsorgoZHuszSFoldesM. Scleromyxedema. J Am Acad Dermatol1999; 41:343–346.
36.
SaigohSTashiroAFujitaS. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology2003; 207:410–411.
37.
VerityMAToopJMcAdamLP. Scleromyxedema myopathy: Histochemical and electron microscopic observations. Am J Clin Pathol1978; 69:446–451.
38.
McAdamLPPearsonCMPittsWH. Papular mucinosis with myopathy, arthritis, and eosinophilia: A histopathologic study. Arthritis Rheum1977; 20:989–996.
RaysonDLustJADuncanA. Scleromyxedema: A complete response to prednisone. Mayo Clin Proc1999; 74:481–484.
41.
RighiASchiavonFJablonskaS. Intravenous immunoglobulins control scleromyxoedema (Concise report). Ann Rheum Dis2002; 61:59–61.
42.
KarimALawlorFBlackMM. Successful treatment of scleromyxoedema with high-dose intravenous immunoglobulin. Clin Exp Dermatol2004; 29:317–318.
43.
SewellWACJollesS. Immunomodulatory action of intravenous immunoglobulin. Immunology2002; 107:387–393.
44.
IbanezCMontoro-RosanoJB. Intravenous immunoglobulin preparations and autoimmune disorders: Mechanism of action. Curr Pharm Biotechnol2003; 4:239–247.
45.
SimonHUSpäthPJ. IVIG — mechanisms of action. Allergy2003; 58:543–552.
46.
ImbachPMorellA. Idiopathic thrombocytopenic purpura (ITP): Immunomodulation by intravenous immunoglobulin (IVIg). Int Rev Immunol1989; 5:181–188.
47.
NewburgerJWTakahashiMBurnsJC. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med1986; 315:341–347.
48.
SatoNSugimuraTAkagiT. Selective high dose gammaglobulin treatment in Kawasaki disease: Assessment of clinical aspects and cost-effectiveness. Pediatr Int1999; 41:1–7.
49.
SaterRARostamiA. Treatment of Guillain–Barre syndrome with intravenous immunoglobulin. Neurology1998; 51:S9–15.
50.
HahnAF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology1998; 51:S16–21.
51.
AzulayJPBlinOPougetJ. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology1994; 44:429–432.
52.
JollesSHughesJWhittakerS. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol1998; 134:80–86.
53.
JollesS. High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol2002; 129:385–389.
54.
PrinsCVittorioCPadillaRS. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: A retrospective, multicenter study. Dermatology2003; 207:96–99.
55.
KozelMMSabroeRA. Chronic urticaria: Aetiology, management and current and future treatment options. Drugs2004; 64:2515–2536.
56.
KumarNRodriguezM. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-la. Mult Scler2004; 10:85–86.
57.
AmemiyaKSemino-MoraCGrangerRP. Downregulation of TGF-betal mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol2000; 94:99–104.
